Copyright
©The Author(s) 2024.
World J Gastroenterol. Jan 7, 2024; 30(1): 34-49
Published online Jan 7, 2024. doi: 10.3748/wjg.v30.i1.34
Published online Jan 7, 2024. doi: 10.3748/wjg.v30.i1.34
Agent class | Agent | Mechanism/pathway | Drug stage | Efficacy | Ref. |
Targets of lymphangiogenic factors | VEGFC/Ad-hVEGF-C | VEGFC-VEGFR3 signaling pathway; increase lymph drainage and bacteria antigen clearance | Animal model | Reduced severity of chronic colitis in terms of histological examination, body weight, endoscopic evaluation, and CDAI than control group | [60] |
COMP-Ang1 | Reduce inflammation-induced lymphangiogenesis and M1 and M2 macrophage infiltration by inhibiting VEGF-C/D expression | Animal model | Less weight loss, fewer clinical signs of colitis, and longer colons than control group | [109] | |
TLR4 inhibitor | C34 | TLR4-PAMP/DAMP discriminatory mechanism | Animal model | Less weight loss, reduced disease activity score and reduced colon shortening in treatment group | [71] |
Anti-trafficking therapies: S1P receptor modulators | Ozanimod | S1P1/5 receptor modulator; induce internalization and degradation of S1P1/5 receptor subtypes | Phase 2 clinical studies in patients with CD | Endoscopic, histological, and clinical improvements within 12 wk of initiating ozanimod therapy in patients with moderate to severe CD | [76] |
Phase 3 clinical studies | Recruiting | NCT03440372, NCT03440385, NCT03464097, NCT03467958 | |||
Etrasimod | S1P1/4/5 receptor modulator | Phase 2/3 clinical studies in patients with CD | Recruiting | NCT04173273 | |
Antiplatelet antibody | GPIb inhibitor | Promote lymphangiogenesis and increase lymphatic vessel densities | Animal model | Suppressed colitis with reduced thickness of the submucosal layer, reduced inflammatory cell infiltration, and reduced histological score | [55] |
Anti-bacterial and its related metabolites or secretions1 | EB8018 | Inhibit bacterial lectin (FimH) to stop the activation of TLR4 and ensuing TNF-α production | Open-label, multicenter, pharmacokinetic Study | Finished without results disclosure | NCT03709628 |
RHB-104 | Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis | Phase 3 study to assess the efficacy and safety of fixed-dose combination RHB-104 | Number of patients in remission at week 16 was higher in RHB-104 compared with placebo | NCT03009396 | |
A randomized, double blind, placebo-controlled, multicenter, parallel group study | Reduction of the total CDAI score to less than 150 at week 26 was significantly higher in RHB-104 than placebo | NCT01951326 | |||
Chemical compound | Artemisinin | Ameliorate inflammation-driven lymphangiogenesis via the VEGFC/VEGFR3 signaling pathway | Animal model | Reduced symptoms of colitis with improved tissue histology, relieved inflammatory edema, and decreased infiltration of inflammatory cells | [110] |
- Citation: Zhou YW, Ren Y, Lu MM, Xu LL, Cheng WX, Zhang MM, Ding LP, Chen D, Gao JG, Du J, Jin CL, Chen CX, Li YF, Cheng T, Jiang PL, Yang YD, Qian PX, Xu PF, Jin X. Crohn’s disease as the intestinal manifestation of pan-lymphatic dysfunction: An exploratory proposal based on basic and clinical data. World J Gastroenterol 2024; 30(1): 34-49
- URL: https://www.wjgnet.com/1007-9327/full/v30/i1/34.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i1.34